You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 SABR planning and delivery variables (N = 42 patients)

From: Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity

Number of fiducials 0 N = 2 (5.0%)*
1 N = 8 (19.0%)
2 N = 5 (12.0%)
3 N = 21 (50.0%)
4 N = 6 (14.0%)
Treatment duration (days) 3 N = 37 (88.1%)
4 N = 1 (2.4%)
5 N = 3 (7.1%)
7 N = 1 (2.4%)
PET scan data used for planning Yes N = 11 (26.0%)
No N = 31 (74.0%)
PTV size (cc) Mean (95% CI) 76.25 (63.83–88.67)
Prescription dose (Gy) Mean (95% CI) 26.77 (19.33–113.39)
Prescription Isodose (%) Mean (95% CI) 67.3 (65.24–69.35).
Percentage Cover (%) Mean (95% CI) 96.6 (95.52–97.66)
Min dose to PTV (Gy) Mean (95% CI) 22.29 (21.0–23.5)
Max dose to PTV (Gy) Mean (95% CI) 40.2 (38.5–41.9)
Mean dose to PTV (Gy) Mean (95% CI) 31.5 (30.8–32.3)
Homogeneity Index (HI) Mean (95% CI) 1.5 (1.45–1.55)
BED (Gy) Mean (95% CI) 50.3 (47.7–53.0)
Fraction dose (Gy per fraction) Mean (95% CI) 8.9 (8.6–9.2)
Delivery time (mins) Mean (95% CI) 71.4 (65.2–77.6)
  1. *alternative planning and delivery strategy used for 2 patients